Результаты поиска

Neurological disorders related to pediatric dengue infection.

In the last decade, Dengue virus has become a major public health concern, with increasing numbers of infections, hospitalizations, and deaths worldwide. The Aedes mosquito vector's migration, aided by adaptation to climate change has allowed Dengue virus to spread into temperate regions. The major impact of the disease occurs in regions with limited resources, creating a significant burden for these countries. There is a growing body of information characterizing the neurological disorders related to pediatric Dengue infection. In addition to reviewing Dengue virus structure, disease diagnost…

Risk Stratification of Dengue Cases Requiring Hospitalization.

Dengue pathogenesis involves immune-driven inflammation that contributes to severe disease progression. This study assessed a machine learning model to identify a minimal, yet highly predictive biomarker set, aiming to support clinical decision-making and patient triage. A total of 48 inflammatory mediators were quantified from plasma samples collected at admission from confirmed dengue patients, classified as either dengue without warning signs (DF) or dengue with warning signs/severe dengue (DWS/SD). A random forest approach was applied to identify the most predictive biomarkers associated w…

Cross Talk between MicroRNAs and Dengue Virus.

Dengue fever (DF) is an endemic infectious tropical disease and is rapidly becoming a global problem. Dengue fever is caused by one of the four dengue virus (DENV) serotypes and is spread by the female Aedes mosquito. Clinical manifestations of DF may range from asymptomatic to life-threatening severe illness with conditions of hemorrhagic fever and shock. Early and precise diagnosis is vital to avoid mortality from DF. A different approach is required to combat DF because of the challenges with the vaccines currently available, which are nonspecific; each is capable of causing cross-reaction …

Epidemiology of Dengue - Puerto Rico, 2010-2024.

Dengue is a mosquitoborne viral illness that can cause acute febrile illness, severe disease, or death. Worldwide, the number of dengue cases is increasing. During the last dengue outbreaks in Puerto Rico throughout 2010-2013, dengue virus (DENV) serotype 1 (DENV-1) predominated, and the largest proportion of cases occurred among adolescents and young adults aged 10-19 years. Dengue case data from January 1, 2010-November 4, 2024, were obtained from the Puerto Rico Department of Health. Bivariate analyses were conducted to evaluate the distribution of cases by patient age, DENV serotype, and h…

Tizoxanide Antiviral Activity on Dengue Virus Replication.

Dengue virus is an important circulating arbovirus in Brazil responsible for high morbidity and mortality worldwide, representing a huge economic and social burden, in addition to affecting public health. In this study, the biological activity, toxicity, and antiviral activity against dengue virus type 2 (DENV-2) of tizoxanide (TIZ) was evaluated in Vero cell culture. TIZ has a broad spectrum of action in inhibiting different pathogens, including bacteria, protozoa, and viruses. Cells were infected for 1 h with DENV-2 and then treated for 24 h with different concentrations of the drug. The qua…

Insights into dengue immunity from vaccine trials.

The quest for an effective dengue vaccine has culminated in two approved vaccines and another that has completed phase 3 clinical trials. However, shortcomings exist in each, suggesting that the knowledge on dengue immunity used to develop these vaccines was incomplete. Vaccine trial findings could refine our understanding of dengue immunity, because these are experimentally derived, placebo-controlled data. Results from these trials suggest that neutralizing antibody titers alone are insufficient to inform protection against symptomatic infection, implicating a role for cellular immunity in p…

Antibody affinity versus dengue morphology influences neutralization.

Different strains within a dengue serotype (DENV1-4) can have smooth, or "bumpy" surface morphologies with different antigenic characteristics at average body temperature (37°C). We determined the neutralizing properties of a serotype cross-reactive human monoclonal antibody (HMAb) 1C19 for strains with differing morphologies within the DENV1 and DENV2 serotypes. We mapped the 1C19 epitope to E protein domain II by hydrogen deuterium exchange mass spectrometry, cryoEM and molecular dynamics simulations, revealing that this epitope is likely partially hidden on the virus surface. We showed the …

Зараженная поджелудочная псевдоцистка после серьезной инфекции денге.

Тяжелая инфекция денге угрожает жизни, поскольку она может привести к таким смертельным осложнениям, как труднопреодолимое кровотечение от коагулопатии, многоорганическая неудача от шока и гемофагоцитический синдром. Поступали сообщения о нетипичных проявлениях сильной инфекции денге, таких как панкреатит, синдром Гильян-Барре, перфорированный виско и миокардит. Однако, насколько нам известно, в литературе никогда не сообщалось о поджелудочной псевдоцистите, связанной с денге. Мы сообщаем о случае заражения поджелудочной псевдоцистикой у пациента с хронической пирексией, брюшной болью и воспал

Совпадение в аннотации оригинала
Severe dengue infection is life threatening as it can result in fatal complications such as intractable bleeding from coagulopathy, multiorgan failure from shock and haemophagocytic syndrome. There have been case reports of atypical manifestation of severe dengue infection such as pancreatitis, Guillian-Barre's syndrome, perforated viscus and myocarditis. Ho…

Crocetin Improves Dengue Virus-Induced Liver Injury.

Dengue virus (DENV) infection is one of the most widespread mosquito-borne viral infections. Liver injury is commonly observed in severe DENV infection, and the present study aimed to examine the efficacy of crocetin treatment in an immunocompetent mouse model of DENV infection exhibiting liver injury. The efficacy of crocetin treatment in DENV-induced liver injury was assessed via both transaminase levels and histopathology analysis. A real-time polymerase chain reaction array was then used to describe the expression of 84 apoptosis-related genes. Using real-time RT-PCR and Western blot analy…

Dengue vaccine development: Global and Indian scenarios.

India is home to nearly a third of the global population at risk of dengue, a viral disease caused by four antigenically and genetically distinct dengue viruses. Clinical illness following dengue virus infection can either be mild and self-limiting dengue fever or severe dengue hemorrhagic fever/dengue shock syndrome, with potentially fatal consequences. A live attenuated vaccine known as Dengvaxia, developed by Sanofi, was licensed in 2015. Following this, long-term follow-up of the Sanofi phase III efficacy trial participants has revealed potential safety concerns. This vaccine, which appear…

Focused dengue vaccine development: outwitting nature's design.

The four DENV serotypes are mosquito-borne pathogens that belong to the Flavivirus genus. These viruses present a major global health burden, being endemic in over 120 countries, causing ∼390 million reported infections yearly, with clinical symptoms ranging from mild fever to severe and potentially fatal hemorrhagic syndromes. Development of a safe and efficacious DENV vaccine is challenging because of the need to induce immunity against all four serotypes simultaneously, as immunity against one serotype can potentially enhance disease caused by a heterotypic secondary infection. So far, live

Dengue virus compartmentalization during antibody-enhanced infection.

Secondary infection with a heterologous dengue virus (DENV) serotype increases the risk of severe dengue, through a process termed antibody-dependent enhancement (ADE). During ADE, DENV is opsonized with non- or sub-neutralizing antibody levels that augment entry into monocytes and dendritic cells through Fc-gamma receptors (FcγRs). We previously reported that co-ligation of leukocyte immunoglobulin-like receptor-B1 (LILRB1) by antibody-opsonized DENV led to recruitment of SH2 domain-containing phosphatase-1 (SHP-1) to dephosphorylate spleen tyrosine kinase (Syk) and reduce interferon stimulat…